课题基金 / 基金详情

Androgenic Inactivation of FKHR in Prostate Cancer

Androgenic Inactivation of FKHR in Prostate Cancer
前列腺癌中 FKHR 的雄激素失活
批准号:
6773246
负责人:
DONALD J. TINDALL
金额:
$25.55万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-08-01 至 2007-05-31

项目摘要

项目成果

DONALD J. TINDALL的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供): 良性前列腺增生(BPH)和前列腺癌是我国男性的两大健康问题。雄激素受体对良性和癌性前列腺细胞的生长和存活都至关重要。雄激素的促有丝分裂作用部分由雄激素诱导的增殖促进蛋白(如增殖细胞核抗原(PCNA)、细胞周期蛋白依赖性激酶2和4)的增加以及细胞周期抑制剂(如细胞周期蛋白依赖性激酶抑制剂p16 ink 4a)的减少介导。虽然雄激素抗凋亡作用的机制细节远未阐明,但最近在我们的实验室和其他实验室已经取得了进展。我们和其他人已经证明,雄激素通过拮抗肿瘤抑制基因PTEN的功能作为生存因子。PTEN下游的一个效应子,叉头转录因子FKHR,通过诱导促凋亡基因的转录在细胞凋亡中起关键作用。我们和其他人已经表明,FKHR的强制表达诱导前列腺癌细胞的凋亡,表明FKHR是前列腺癌细胞中关键的促凋亡因子。我们的数据表明,雄激素消除FKHR诱导的前列腺癌细胞死亡。此外,我们已经证明雄激素通过调节溶酶体介导的FKHR蛋白水解来抑制FKHR的活性。因此,我们推测雄激素拮抗前列腺细胞死亡至少部分通过其对FKHR促凋亡功能的抑制作用。为了验证这一假设,我们建议(1)确定FKHR蛋白中的蛋白水解切割位点;(2)鉴定切割FKHR的雄激素调节蛋白酶;(3)确定雄激素对FKHR作用的阻断是否有利于前列腺癌细胞的死亡。这些研究结果应加强我们对雄激素对正常和恶性前列腺细胞生长和存活的作用的理解。此外,这种新蛋白的鉴定将使我们能够更好地操纵BPH和前列腺癌中的雄激素调节事件。
英文摘要
DESCRIPTION (provided by applicant): Benign prostate hyperplasia (BPH) and prostate cancer are two major health problems of men in this country. The androgen receptor is critical for both growth and survival of benign and cancerous prostate cells. Mitogenic effects of androgens are mediated in part by androgen-induced increases in proliferation-promoting proteins, such as proliferating cell nuclear antigen (PCNA), cyclin-dependent kinases 2 and 4, as well as decreases in cell cycle inhibitors, such as cyclin-dependent kinase inhibitor p16 ink4a. Although the mechanistic details of the anti-apoptotic effects of androgens are far from elucidated, progress has been made recently in our laboratory and others. We and others have demonstrated that androgens act as survival factors by antagonizing the function of the tumor suppressor gene PTEN. An effector downstream of PTEN, the forkhead transcription factor FKHR, plays a critical role in apoptosis by inducing the transcription of proapoptotic genes. We and others have shown that forced expression of FKHR induces apoptosis in prostate cancer cells, suggesting that FKHR is a critical pro-apoptotic player in prostate cancer cells. Our data have demonstrated that androgens abrogate FKHR-induced death of prostate cancer cells. Moreover, we have demonstrated that androgens inhibit the activity of FKHR by regulating lysosome-mediated proteolysis of this protein. Thus, we hypothesize that androgens antagonize death of prostate cells at least in part via their inhibitory effects on the pro-apoptotic function of FKHR. To test this hypothesis, we propose to (1) determine the proteolytic cleavage site in the FKHR protein; (2) identify the androgen-regulated protease(s) that cleaves FKHR; (3) determine whether blockage of the effect of androgens on FKHR favors the death of prostate cancer cells. These findings should enhance our understanding of the action of androgens on growth and survival of both normal and malignant prostate cells. Also, identification of such novel proteins will enable us to better manipulate androgen-regulated events in BPH and prostate cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Administrative Core
  • 批准号:
    7729559
  • 项目类别:
  • 资助金额:
    $12.73万
  • 财政年份:
    2008
  • 负责人:
    DONALD J. TINDALL
  • 依托单位:
Developemental Research Program
  • 批准号:
    7729587
  • 项目类别:
  • 资助金额:
    $8.96万
  • 财政年份:
    2008
  • 负责人:
    DONALD J. TINDALL
  • 依托单位:
Career Development Program
  • 批准号:
    7729595
  • 项目类别:
  • 资助金额:
    $4.48万
  • 财政年份:
    2008
  • 负责人:
    DONALD J. TINDALL
  • 依托单位:
Androgenic Inactivation of FOXO1 in Prostate Cancer
  • 批准号:
    7624312
  • 项目类别:
  • 资助金额:
    $26.34万
  • 财政年份:
    2003
  • 负责人:
    DONALD J. TINDALL
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
  • 批准号:
    31970691
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2019
  • 负责人:
    张胜萍
  • 依托单位:
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
  • 批准号:
    31900527
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2019
  • 负责人:
    孙磊
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位: